Skip to main content
Premium Trial:

Request an Annual Quote

Case Western, TGen to Use Affy Arrays in Diabetes Study

NEW YORK (GenomeWeb News) – Case Western Reserve University and the Translational Genomics Research Institute will use Affymetrix’s Human SNP Array 6.0 to study genetic pathways associated with a certain complication of diabetes, Affy said today.
The two institutions will use Affy’s arrays to focus on finding genetic links to diabetic nephropathy using data from a study by the National Institute of Diabetes and Digestive and Kidney Diseases.
The Family Investigation of Nephropathy and Diabetes (FIND) Consortium research program stretched over five years and involved 11 different recruitment centers and 10,000 subjects. The FIND Consortium has identified several genetic variants linked to nephropathy in African-Americans, European-Americans, Mexican-Americans, and American Indians.
The researchers involved in this end of the project hope to use the information to develop therapies to prevent or control nephropathy, and to identify people at risk for progressive renal disease. 
"Diabetes continues to mystify researchers because both genetic and environmental factors appear to play significant roles in the manifestation of the disease,” Affymetrix President Kevin King said in a statement.
Financial terms of the agreement were not released.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.